Bair Teresa Brophy 4

What Happened

• Teresa Bair, Chief Legal Officer of Kura Oncology, sold a total of 11,208 shares on January 27, 2026 in three open-market transactions at $8.46 per share, for aggregate proceeds of approximately $94,828. The individual sales reported were 4,096 shares ($34,655), 2,335 shares ($19,756), and 4,777 shares ($40,417). These are reported as sales (code S) and, per the filing footnotes, were sell-to-cover transactions to satisfy tax withholding on vested RSUs.

Key Details

• Transaction date and price: Jan 27, 2026 — all three sales at $8.46 per share.
• Shares sold: 4,096; 2,335; 4,777 — total 11,208 shares; total proceeds ≈ $94,828.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnotes: F1, F2, F3 indicate each sale was a sell-to-cover for taxes tied to RSUs that vested on 1/2/25, 2/16/23, and 1/2/24, respectively.
• Filing timeliness: Report filed on 2026-01-27 (same day as the report period), so no late filing indicated.

Context

• Sell-to-cover transactions are routine: when restricted stock units vest, companies often sell a portion of the shares to cover required tax withholding. Such sales are administrative and don’t necessarily signal the insider’s view on the company’s prospects. Purchases or new grants tend to be more informative about insider conviction.